EI
NBIX icon

Ethic Inc’s Neurocrine Biosciences NBIX Stock Holding History

Ethic Inc’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$290K Buy
+1,718
New +$255K ﹤0.01% 1144
2025
Q2 		– Sell
-2,545
Closed -$272K – 1273
2025
Q1 		$272K Sell
2,545
-1,647
-39% -$209K 0.01% 975
2024
Q4 		$572K Buy
4,192
+1,073
+34% +$133K 0.01% 757
2024
Q3 		$430K Buy
3,119
+207
+7% +$28.4K 0.01% 797
2024
Q2 		$401K Sell
2,912
-207
-7% -$28.4K 0.01% 814
2024
Q1 		$430K Sell
3,119
-1,337
-30% -$183K 0.01% 796
2023
Q4 		$587K Buy
4,456
+811
+22% +$93.4K 0.02% 688
2023
Q3 		$410K Buy
+3,645
New +$384K 0.01% 737

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Ethic Inc's NBIX Position: Q2 2026 in Review

Ethic Inc opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1,718 shares worth $290K. The stake represents ﹤0.01% of the portfolio and ranks #1144 among its holdings. This is a return to the name: Ethic Inc previously reported a position in NBIX as recently as Q1 2025.

Ethic Inc first reported a position in NBIX in Q3 2023 and has held it in 8 quarters since. The position peaked at $587K in Q4 2023. 778 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Ethic Inc held 1,718 shares of Neurocrine Biosciences worth $290K as of Q2 2026.
  • Neurocrine Biosciences was a new Ethic Inc position in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Ethic Inc's portfolio in Q2 2026, its #1144 holding.
  • Ethic Inc first reported a position in Neurocrine Biosciences in Q3 2023 and has held it in 8 quarters since.
  • Ethic Inc's Neurocrine Biosciences position peaked at $587K in Q4 2023.
  • 778 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Ethic Inc's 13F filing for Q2 2026, filed 29 Jul 2026.